^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Cabometyx (cabozantinib tablet)

    i
    Other names: XL184 tablet, BMS-907351 tablet, XL-184, BMS907351, BMS 907351, XL184, XL 184
    Company:
    Exelixis, Ipsen, Royalty, Takeda
    Drug class:
    Multi-tyrosine kinase inhibitor
    Related drugs:
    1d
    Multi-target Agents in Complex Diseases: From Design Principles to Therapeutic Applications. (PubMed, Curr Drug Targets)
    Multi-target agents are no longer constrained by single-target effects; however, issues of balanced potency, ADMET, and control still exist. The combination of AI, quantum computing, and precision polypharmacology may enable more effective multi-target interventions to address unmet demands in complex diseases.
    Journal
    |
    APP (Amyloid Beta Precursor Protein)
    |
    imatinib • sunitinib • Cabometyx (cabozantinib tablet)
    3d
    Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer (clinicaltrials.gov)
    P2, N=50, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
    Trial suspension
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
    6d
    Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study (clinicaltrials.gov)
    P3, N=654, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Jul 2029 | Trial primary completion date: Jun 2026 --> Jul 2029
    Trial completion date • Trial primary completion date
    |
    IFNA1 (Interferon Alpha 1)
    |
    Bavencio (avelumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    6d
    Therapeutic Drug Monitoring and Model-Informed Precision Dosing of Oral TKIs and PARP Inhibitors: A Practical Framework for Clinical Implementation. (PubMed, Clin Pharmacokinet)
    High-level evidence, including prospective interventional studies, supports exposure-guided dosing for imatinib and sunitinib, demonstrating improved molecular or clinical outcomes when predefined trough concentration targets are achieved. For alectinib, cabozantinib, trametinib, and lenvatinib, consistent exposure-response or exposure-toxicity relationships and pragmatic concentration thresholds support selective implementation, although randomized validation remains limited. For agents such as osimertinib, brigatinib, olaparib, and niraparib, monitoring appears most clinically relevant in toxicity-driven scenarios rather than for efficacy optimization. In contrast, lorlatinib currently lacks a clearly defined therapeutic window, limiting routine applicability...In conclusion, therapeutic drug monitoring and model-informed precision dosing are ready for selective clinical adoption in a subset of oral targeted therapies. Future prospective trials integrating pharmacometric tools with patient-centered outcomes are required to refine exposure targets and expand evidence-based implementation.
    Review • Journal
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    Lynparza (olaparib) • Mekinist (trametinib) • Tagrisso (osimertinib) • imatinib • sunitinib • Alecensa (alectinib) • Lorbrena (lorlatinib) • Lenvima (lenvatinib) • Zejula (niraparib) • Cabometyx (cabozantinib tablet) • Alunbrig (brigatinib)
    7d
    Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer (clinicaltrials.gov)
    P3, N=718, Recruiting, SWOG Cancer Research Network | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • Lenvima (lenvatinib) • Cabometyx (cabozantinib tablet) • axitinib • ABP 206 (nivolumab biosimilar) • Cdactin-O (CBM588) • Opdivo Qvantig (nivolumab and hyaluronidase-nvhy)
    8d
    Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery (clinicaltrials.gov)
    P2, N=101, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
    10d
    CaboLu: Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=33, Suspended, University of Utah | Trial completion date: May 2028 --> Dec 2028 | Recruiting --> Suspended | Trial primary completion date: May 2026 --> Dec 2026
    Trial completion date • Trial suspension • Trial primary completion date
    |
    FOLH1 positive
    |
    Cabometyx (cabozantinib tablet) • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    13d
    Discovery of Casdatifan, Part II: A Potent and Orally Bioavailable Inhibitor of Hypoxia Inducible Factor-2α. (PubMed, J Med Chem)
    Casdatifan has shown promising clinical activity in the ARC-20 ccRCC platform study, both as monotherapy and in combination with the VEGFR tyrosine kinase inhibitor (TKI) cabozantinib. Currently, casdatifan is being evaluated in a Phase 3 trial in combination with cabozantinib (NCT07011719) in patients with advanced ccRCC.
    Journal
    |
    EPAS1 (Endothelial PAS domain protein 1)
    |
    Cabometyx (cabozantinib tablet) • casdatifan (AB521)
    16d
    Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study (clinicaltrials.gov)
    P3, N=5000, Not yet recruiting, Exelixis
    New P3 trial
    |
    Opdivo (nivolumab) • Tecentriq (atezolizumab) • enzalutamide • Cabometyx (cabozantinib tablet) • abiraterone acetate • prednisone • zanzalintinib (XL092)
    17d
    CaboCombo: A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults (clinicaltrials.gov)
    P=N/A, N=311, Completed, Ipsen | Active, not recruiting --> Completed | Trial completion date: Nov 2026 --> Oct 2025
    Trial completion • Trial completion date
    |
    Opdivo (nivolumab) • Cabometyx (cabozantinib tablet)
    17d
    Clinical Outcomes and Therapeutic Response in Adult TFE3-Related Renal Cell Carcinoma: A Case Series From a Tertiary Cancer Center in Southern India. (PubMed, Cureus)
    Advanced disease shows unpredictable response to targeted therapy, underscoring the need for further molecular characterization and prospective studies to optimize management strategies. Long-term surveillance remains essential due to the risk of late recurrence.
    Clinical data • Journal
    |
    TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • CA9 (Carbonic anhydrase 9) • VIM (Vimentin) • MME (Membrane Metalloendopeptidase) • MLANA (Melan-A)
    |
    Cabometyx (cabozantinib tablet)
    25d
    Intensified Monitoring of PhArmacology of Cabozantinib as a tool for Toxicity management in patients with renal cell carcinoma (2026-525267-40-00)
    P4, N=216, Not yet recruiting, Centro Di Riferimento Oncologico Di Aviano
    New P4 trial • Adverse events
    |
    Opdivo (nivolumab) • Cabometyx (cabozantinib tablet)